Takeda's Provigil sales force takes a hit

Share this article:
At least 500 Takeda Pharmaceutical employees who market Provigil in the US will be impacted by the announcement from Cephalon that it will end its co-promotion agreement with Takeda, Bloomberg reported. 

The partnership on the sleep-disorder agent Provigil is slated to end November 1. Takeda would not confirm the contents of the Bloomberg report, however, a Security and Exchange Commission (SEC) filing reports that 500 Takeda employees could be targeted, according to a Takeda spokesperson.  

Frazer, PA-based Cephalon cited a failure to reach a targeted goal of $850 million in sales this year as the reason for ending the agreement with Takeda. Both companies agreed that the co-promotion agreement could be severed if sales were lower than $850 million in the second year.

Cephalon is expected to add 270 sales representatives in 2009. According to industry sources, sales of Provigil rose 9.6% in the second quarter of this year to $234.8 million.

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.